Insmed INSM Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| R&D by Product | ||||||
| ARIKAYCE external R&D expenses | $37.94M-8.4% | $41.44M-12.6% | $47.42M-13.1% | $54.57M-6.7% | $58.46M-3.0% | |
| Brensocatib external R&D expenses | $94.34M-2.3% | $96.52M-1.0% | $97.53M+2.2% | $95.47M-4.3% | $99.71M+1.2% | |
| Other external R&D expenses | $134.46M+3.5% | $129.87M+1.0% | $128.6M+8.1% | $118.94M+12.8% | $105.41M+16.3% | |
| TPIP external R&D expenses | $122.39M+29.9% | $94.2M+18.8% | $79.3M+18.0% | $67.18M+9.6% | $61.31M-7.0% | |
| Product revenues, net by Geography | ||||||
| International | $160.82M+4.8% | $153.47M+6.4% | $144.24M+10.5% | $130.49M— | —— | |
| US | $658.74M+45.4% | $452.95M+49.6% | $302.78M+13.1% | $267.62M+1.9% | $262.73M+3.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insmed break its business down?
- Insmed (INSM) reports r&d by product across 5 parts — ARIKAYCE external R&D expenses, Brensocatib external R&D expenses, INS1148, Other external R&D expenses and TPIP external R&D expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Insmed's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insmed's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
